Vor Biopharma (NASDAQ:VOR) Posts Quarterly Earnings Results, Misses Expectations By $0.11 EPS

Vor Biopharma (NASDAQ:VOR) announced its earnings results on Tuesday. The company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.69) by ($0.11), Zacks reports.

Vor Biopharma Stock Performance

Shares of VOR traded down $0.39 during mid-day trading on Tuesday, hitting $22.98. The stock had a trading volume of 77,701 shares, compared to its average volume of 1,068,374. The business has a fifty day moving average price of $17.80 and a 200-day moving average price of $15.84. Vor Biopharma has a 52 week low of $6.50 and a 52 week high of $50.20.

Institutional Investors Weigh In On Vor Biopharma

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in VOR. RA Capital Management L.P. lifted its holdings in Vor Biopharma by 172.7% during the fourth quarter. RA Capital Management L.P. now owns 5,404,998 shares of the company’s stock valued at $70,697,000 after purchasing an additional 3,422,697 shares during the last quarter. Paradigm Biocapital Advisors LP purchased a new stake in shares of Vor Biopharma during the 4th quarter valued at approximately $22,890,000. Caligan Partners LP bought a new position in Vor Biopharma in the 4th quarter worth approximately $12,100,000. Sphera Funds Management LTD. bought a new position in shares of Vor Biopharma in the fourth quarter worth $5,368,000. Finally, Laurion Capital Management LP purchased a new stake in Vor Biopharma during the 4th quarter worth about $4,150,000. 97.29% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts have commented on the stock. Jefferies Financial Group upgraded shares of Vor Biopharma to a “strong-buy” rating in a research note on Thursday, April 30th. HC Wainwright restated a “buy” rating and issued a $31.00 target price on shares of Vor Biopharma in a research note on Monday, May 18th. Wall Street Zen lowered Vor Biopharma from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Weiss Ratings raised Vor Biopharma from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, June 30th. Finally, Wedbush lifted their price target on Vor Biopharma from $15.00 to $18.00 and gave the stock a “neutral” rating in a report on Thursday, May 14th. Two investment analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Vor Biopharma currently has a consensus rating of “Moderate Buy” and a consensus price target of $42.25.

Vor Biopharma Company Profile

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).